ICE Biopharma in-licenses, registers and commercialises specialty and rare disease drugs in Europe and Canada, to ensure that European and Canadian patients have access to the breakthrough therapies they deserve.
Products, services, technology
ICE Biopharma is looking to in-license late-stage (Phase III / Pre-registration) innovative therapeutics for rare and specialty indications for the European and Canadian markets.
Cooperation possibilities
ICE Biopharma is the in-licensing partner of choice for Biotechs wishing to launch their innovative medicines in Europe & Canada.
We will establish a direct commercial presence in major markets and act as a single point of contact for distributors in other markets.
- https://icebiopharma.com/
- +41 79 592 23 17
- Send an email
- Francis Marsland
Some insights
By ensuring that European and Canadian patients have access to the innovative therapeutics they deserve.
ICE Biopharma is a passionate and experienced team, forged in international biotech, with a compelling track record of launching innovative medicines in rare and specialty indications.
ICE Biopharma's role models are science-based biotechnology companies who make breakthrough developments in meeting unmet needs in rare diseases.
Our core strengths are business development, licensing and commercialisation of high technology therapeutics.
We strive to make contracts with innovative biotechnology companies.
The Swiss biotech ecosystem is a rich source of key talents and an emerging center for later-stage therapeutic development.
Biotech executives with late-stage or in-market therapeutics assets avaliable for partnering in Europe and Canada.